Akari Therapeutics Plc Sponsored ADR Stock News
$2.08
6.73%
yesterday
Nasdaq,
Nov 15, 10:00 pm CET
Akari Therapeutics Plc Sponsored ADR Stock News
Neutral
GlobeNewsWire
●
one day ago
- Secures $3.2m in PIPE Financing - - $50m Term Sheet Obtained for Available Financing under Equity Line of Credit -
Neutral
GlobeNewsWire
●
8 days ago
BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. At a General Meeting held in relation to the merger at 9:00 a.m. Eastern Ti...
Neutral
GlobeNewsWire
●
3 months ago
Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders
Neutral
GlobeNewsWire
●
3 months ago
Pre-IND meeting with FDA completed with positive feedback on clinical and nonclinical development plans for PAS-nomacopan in treatment of geographic atrophy Pre-IND meeting with FDA completed with positive feedback on clinical and nonclinical development plans for PAS-nomacopan in treatment of geographic atrophy
Neutral
GlobeNewsWire
●
6 months ago
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
